This research evaluated the effect of Maraviroc and/or Favipiravir plus systemic steroids versus systemic steroids only on the viral load of adults with severe COVID-19: clinical trials .COVID-19 has
Background Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent in vitro activity against SARS-CoV-2 virus. The safety and efficacy of halofuginone in Covid-19 patients
*four of the 89 adherent participants did not have evaluable HCV RNA at week 4 and were excluded from this analysis, ¥includes one participant with mixed genotype 1/3 infection, £row percentage (e.g.
